Anti-Mouse CXCL9 (Clone MIG-2F5-5) - Purified in vivo GOLD™ Functional Grade

Product Code: LEI-C793

Code	Size	Price

LEI-C793-1.0mg

1.0 mg

£175.00

Quantity:

LEI-C793-5.0mg

5.0 mg

£380.00

Quantity:

LEI-C793-25mg

25 mg

£1,014.00

Quantity:

LEI-C793-50mg

50 mg

£1,556.00

Quantity:

LEI-C793-100mg

100 mg

£2,159.00

Quantity:

Prices exclude any Taxes / VAT

Overview

Host Type: Hamster

Antibody Isotype: IgG

Antibody Clonality: Monoclonal

Antibody Clone: MIG-2F5-5

Regulatory Status: RUO

Target Species: Mouse

Applications:

Flow Cytometry
Immunofluorescence (IF)
In Vivo Assay
Neutralisation

Shipping:

2-8°C

Storage:

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.

Further Information

Antigen Distribution:

CXCL9 is mainly secreted by macrophages, monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-γ and is also expressed in intratumoral dendritic cells.

Concentration:

? 5.0 mg/ml

Conjugate/Tag/Label:

in vivo GOLD™, Purified in vivo Functional Grade

Format:

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Formulation:

Immunogen:

Mouse plasmacytoid dendritic cells

Long Description:

CXCL9 is a chemokine, which are small 8-15 kDa proteins that function in immune responses1. CXCL9, -10, -11 and their receptor CXCR3 regulate immune cell migration, differentiation, and activation, leading to tumor suppression in the paracrine axis. However, in the autocrine axis, they may be involved in tumor growth and metastasis. The CXCL9, -10, -11/CXCR3 axis also regulates differentiation of na?ve T cells to T helper 1 (Th1) cells. CXCL9, -10, and -11 are usually expressed at low levels but are upregulated by cytokine stimulation. CXCL9 is dependent on IFNγ for expression2. CXCL9 is also capable of direct antimicrobial activity against pathogen infection3. CXCL9 is secreted by macrophages4, monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-γ1 and is also expressed in intratumoral dendritic cells5. CXCL9 is also detectable in CD103+ conventional dendritic cells (cDCs) isolated from transgenic murine MMTV-PyMT tumors following in vivo administration of brefeldin A5. Additionally, CXCL9 is detectable in myeloid cells following ex vivo stimulation with IFN-γ. Furthermore, CXCL9 expression is enhanced in CD8α+ cDC1s when anti-TIM-3 is added. Neutralizing antibodies against Galectin-9 lead to an increase in CXCL9 expression comparable to that induced by anti-TIM-3 antibody. Additionally, endothelial cell expression of CXCL9 is strongly increased in liver sinusoidal endothelial cells isolated from nonalcoholic steatohepatitis mouse livers6. MIG-2F5-5 was generated by immunizing male Armenian hamsters with recombinant murine CXCL9, and specificity was confirmed by ELISA7.

NCBI Gene:

4283

Purity:

?95% monomer by analytical SEC, >95% by SDS Page

Target:

CXCR3

References

1. Tokunaga R, Zhang W, Naseem M, et al. Cancer Treat Rev. 63:40-47. 2018. 2. Cole KE, Strick CA, Paradis TJ, et al. J Exp Med. 187: 2009?2021. 1998. 3. Reid-Yu SA, Tuinema BR, Small CN, et al. PLoS Pathog. 11(2):e1004648. 2015. 4. Marcovecchio PM, Thomas G, Salek-Ardakani S. J Immunother Cancer. 9(2):e002045. 2021. 5. de Mingo Pulido ?, Gardner A, Hiebler S, et al. Cancer Cell. 33(1):60-74.e6. 2018. 6. Xiong X, Kuang H, Ansari S, et al. Mol Cell. 75(3):644-660.e5. 2019. 7. Krug A, Uppaluri R, Facchetti F, et al. J Immunol. 169(11):6079-6083. 2002. 8. Asai A, Tsuda Y, Kobayashi M, et al. Infect Immun. 78(10):4311-4319. 2010.